Mastodon

Hesperidin + Diosmin (Tablets) Instructions for Use

ATC Code

C05CA53 (Diosmin in combination with other drugs)

Active Substances

Diosmin (Rec.INN registered by WHO)

Hesperidin (Grouping name)

Clinical-Pharmacological Group

Venotonic drug

Pharmacotherapeutic Group

Venotonic and venoprotective agent

Pharmacological Action

A combined agent with angioprotective and venotonic action, containing bioflavonoids.

It reduces venous distensibility, increases venous tone, and reduces venous stasis; it decreases capillary permeability and fragility and increases their resistance; it improves microcirculation and lymphatic drainage.

With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of organic and functional nature.

Indications

Symptomatic treatment of venous insufficiency of the lower extremities: sensation of heaviness and pain in the legs.

Symptomatic treatment of acute hemorrhoids.

ICD codes

ICD-10 code Indication
I87.2 Venous insufficiency (chronic) (peripheral)
K64 Hemorrhoids and perianal venous thrombosis
ICD-11 code Indication
BD74.Z Chronic venous insufficiency of lower extremities, unspecified
DB6Z Hemorrhoids or perianal venous diseases, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets

It is taken orally.

For venous-lymphatic insufficiency, the daily dose is 900 mg of diosmin + 100 mg of hesperidin.

The frequency of administration is 2 times/day (at midday and in the evening during meals).

For acute hemorrhoids, during the first 4 days the daily dose is 2.7 g of diosmin + 300 mg of hesperidin (in 2 doses in the morning and evening), during the following 3 days the daily dose is 1.8 g of diosmin + 200 mg of hesperidin (in 2 doses in the morning and evening).

Adverse Reactions

From the digestive system: often – diarrhea, nausea, vomiting, dyspepsia; infrequently – colitis.

From the CNS rarely – dizziness, headache, general malaise.

From the skin: rarely – rash, itching, urticaria; unspecified frequency – isolated edema of the face, lips, eyelids; in exceptional cases – angioedema.

Contraindications

The period of lactation (breastfeeding), hypersensitivity to diosmin and hesperidin.

Use in Pregnancy and Lactation

To date, there have been no reports of any adverse effects when using this combination in pregnant women.

In experimental studies, no teratogenic effects of the Diosmin+Hesperidin combination were observed.

Use is contraindicated during lactation (breastfeeding), as it is not known whether Diosmin and Hesperidin are excreted in breast milk.

Special Precautions

In case of hemorrhoid exacerbation, the use of this combination does not replace specific treatment for other anal disorders.

The duration of treatment should not exceed the recommended periods.

If symptoms do not disappear after short-term therapy, a proctological examination should be performed and the ongoing therapy should be reviewed.

In the presence of venous circulation disorders, the maximum treatment effect is achieved by combining it with a healthy, well-balanced lifestyle, which preferably includes avoiding prolonged sun exposure, prolonged standing, as well as reducing excess body weight, walking, and in some cases – wearing special stockings that improve blood circulation.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Binnopharm JSC (Russia)

Manufactured By

Aliym, JSC (Russia)

Dosage Form

Bottle OTC Icon Hesperidin + Diosmin Film-coated tablets 100 mg+900 mg: 9, 10, 15, 18, 20, 27, 30, 36, 40, 45, 50, 54, 60, 63, 70, 72, 75, 80, 81, 90, 105, 120, or 135 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets from yellow to brownish-yellow in color, biconvex, oblong in shape with rounded ends, with a score; on the cross-section, the core is from grayish-yellow to brownish-gray in color.

1 tab.
Diosmin 900 mg
Hesperidin 100 mg

Excipients : microcrystalline cellulose PH101, sodium carboxymethyl starch (sodium starch glycolate), gelatin, talc, magnesium stearate.

Excipients of the tablet coating hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol 6000), sodium lauryl sulfate, magnesium stearate, titanium dioxide, yellow iron oxide dye.

9 pcs. – blister packs (1, 2, 3, 4, 5, 6, 7, 8, 9) – cardboard packs.
10 pcs. – blister packs (1, 2, 3, 4, 5, 6, 7, 8, 9) – cardboard packs.
15 pcs. – blister packs (1, 2, 3, 4, 5, 6, 7, 8, 9) – cardboard packs.

Marketing Authorization Holder

Binnopharm JSC (Russia)

Manufactured By

Aliym, JSC (Russia)

Dosage Form

Bottle OTC Icon Hesperidin + Diosmin Film-coated tablets, 100 mg+900 mg: 9, 10, 18, 20, 27, 30, 36, 40, 45, 50, 54, 60, 63, 70, 72, 75, 80, 81, 90, 105, 120, or 135 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets from yellow to brownish-yellow in color, biconvex, oblong in shape with rounded ends, with a score; on the cross-section, the core is from grayish-yellow to brownish-gray in color.

1 tab.
Hesperidin 100 mg
Diosmin 900 mg

Excipients : microcrystalline cellulose type 101, sodium carboxymethyl starch (sodium starch glycolate), gelatin, talc, magnesium stearate.

Excipients of the coating: hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol), sodium lauryl sulfate, magnesium stearate, titanium dioxide, yellow iron oxide dye.

9 pcs. – blister packs (1) – cardboard packs.
9 pcs. – blister packs (2) – cardboard packs.
9 pcs. – blister packs (3) – cardboard packs.
9 pcs. – blister packs (4) – cardboard packs.
9 pcs. – blister packs (5) – cardboard packs.
9 pcs. – blister packs (6) – cardboard packs.
9 pcs. – blister packs (7) – cardboard packs.
9 pcs. – blister packs (8) – cardboard packs.
9 pcs. – blister packs (9) – cardboard packs.
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (7) – cardboard packs.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (9) – cardboard packs.
15 pcs. – blister packs (1) – cardboard packs.
15 pcs. – blister packs (2) – cardboard packs.
15 pcs. – blister packs (3) – cardboard packs.
15 pcs. – blister packs (4) – cardboard packs.
15 pcs. – blister packs (5) – cardboard packs.
15 pcs. – blister packs (6) – cardboard packs.
15 pcs. – blister packs (7) – cardboard packs.
15 pcs. – blister packs (8) – cardboard packs.
15 pcs. – blister packs (9) – cardboard packs.

Marketing Authorization Holder

Kron, LLC (Russia)

Manufactured By

Avva Rus, JSC (Russia)

Dosage Forms

Bottle OTC Icon Hesperidin + Diosmin Film-coated tablets, 50 mg+450 mg: 20, 30, 40, 45, 60, or 90 pcs.
Film-coated tablets, 100 mg+900 mg: 30 or 60 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets from yellow with a brownish tint to light brown in color, capsule-shaped, biconvex; on the cross-section, the core is from grayish-yellow to brownish-gray in color; inclusions are allowed.

1 tab.
Hesperidin* 50 mg
Diosmin* 450 mg

* calculated as 100% substance.

Excipients : crospovidone (XL-10) – 45.5 mg, sodium stearyl fumarate – 13 mg, talc – 6.5 mg, microcrystalline cellulose 102 – up to a core tablet weight of 650 mg.

Composition of the film coating mixture for film coating “Opadry® 20A220058 yellow” [hypromellose 2910 – 33.75%, hyprolose – 33.75%, talc – 20%, titanium dioxide – 11.1%, yellow iron oxide dye – 1.4%] – up to a coated tablet weight of 665 mg.

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
15 pcs. – blister packs (2) – cardboard packs.
15 pcs. – blister packs (3) – cardboard packs.
15 pcs. – blister packs (4) – cardboard packs.
15 pcs. – blister packs (6) – cardboard packs.

Film-coated tablets from yellow with a brownish tint to light brown in color, capsule-shaped, biconvex, with a score; on the cross-section, the core is from grayish-yellow to brownish-gray in color; inclusions are allowed.

1 tab.
Hesperidin* 100 mg
Diosmin* 900 mg

* calculated as 100% substance.

Excipients : crospovidone (XL-10) – 91 mg, sodium stearyl fumarate – 26 mg, talc – 13 mg, microcrystalline cellulose 102 – up to a core tablet weight of 1300 mg.

Composition of the film coating mixture for film coating “Opadry® 20A220058 yellow” [hypromellose 2910 – 33.75%, hyprolose – 33.75%, talc – 20%, titanium dioxide – 11.1%, yellow iron oxide dye – 1.4%] – up to a coated tablet weight of 1330 mg.

10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.

Marketing Authorization Holder

Salvus, LLC (Russia)

Manufactured By

Biopharmkombinat, LLC (Russia)

Dosage Forms

Bottle OTC Icon Hesperidin + Diosmin Film-coated tablets, 50 mg+450 mg: 20, 30, 40, 45, 50, 60, 70, 75, 80, 90, 105, 120, or 135 pcs.
Film-coated tablets, 100 mg+900 mg: 20, 30, 40, 45, 50, 60, 70, 75, 80, 90, 105, 120, or 135 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets biconvex, coated with an orange-pink film coating, oblong in shape with rounded ends; on the cross-section, the core is from grayish-yellow to brownish-gray in color.

1 tab.
Hesperidin 50 mg
Diosmin 450 mg

Excipients : microcrystalline cellulose (type 102), sodium carboxymethyl starch (sodium starch glycolate), gelatin, talc, magnesium stearate.

Excipients of the tablet coating: Hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol 6000), sodium lauryl sulfate, magnesium stearate, titanium dioxide, red iron oxide dye, yellow iron oxide dye.

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (7) – cardboard packs.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (9) – cardboard packs.
15 pcs. – blister packs (2) – cardboard packs.
15 pcs. – blister packs (3) – cardboard packs.
15 pcs. – blister packs (4) – cardboard packs.
15 pcs. – blister packs (5) – cardboard packs.
15 pcs. – blister packs (6) – cardboard packs.
15 pcs. – blister packs (7) – cardboard packs.
15 pcs. – blister packs (8) – cardboard packs.
15 pcs. – blister packs (9) – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
45 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
70 pcs. – jars – cardboard packs.
75 pcs. – jars – cardboard packs.
80 pcs. – jars – cardboard packs.
90 pcs. – jars – cardboard packs.
105 pcs. – jars – cardboard packs.
120 pcs. – jars – cardboard packs.
135 pcs. – jars – cardboard packs.

Film-coated tablets biconvex, coated with an orange-pink film coating, oblong in shape with rounded ends; on the cross-section, the core is from grayish-yellow to brownish-gray in color.

1 tab.
Hesperidin 100 mg
Diosmin 900 mg

Excipients : microcrystalline cellulose (type 102), sodium carboxymethyl starch (sodium starch glycolate), gelatin, talc, magnesium stearate.

Excipients of the tablet coating: Hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol 6000), sodium lauryl sulfate, magnesium stearate, titanium dioxide, red iron oxide dye, yellow iron oxide dye.

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (7) – cardboard packs.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (9) – cardboard packs.
15 pcs. – blister packs (2) – cardboard packs.
15 pcs. – blister packs (3) – cardboard packs.
15 pcs. – blister packs (4) – cardboard packs.
15 pcs. – blister packs (5) – cardboard packs.
15 pcs. – blister packs (6) – cardboard packs.
15 pcs. – blister packs (7) – cardboard packs.
15 pcs. – blister packs (8) – cardboard packs.
15 pcs. – blister packs (9) – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
45 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
70 pcs. – jars – cardboard packs.
75 pcs. – jars – cardboard packs.
80 pcs. – jars – cardboard packs.
90 pcs. – jars – cardboard packs.
105 pcs. – jars – cardboard packs.
120 pcs. – jars – cardboard packs.
135 pcs. – jars – cardboard packs.

Marketing Authorization Holder

Formula-FR, LLC (Russia)

Manufactured By

Avva Rus, JSC (Russia)

Dosage Forms

Bottle OTC Icon Hesperidin + Diosmin Film-coated tablets, 50 mg+450 mg: 20, 30, 40, 45, 60, or 90 pcs.
Film-coated tablets, 100 mg+900 mg: 20, 30, 40, 45, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets from yellow with a brownish tint to light brown in color, capsule-shaped, biconvex; the cross-section shows a core from grayish-yellow to brownish-gray in color; inclusions are allowed.

1 tab.
Hesperidin 50 mg
Diosmin 450 mg

Excipients: crospovidone (XL-10) – 45.5 mg, sodium stearyl fumarate – 13 mg, talc – 6.5 mg, microcrystalline cellulose 102 – up to a core tablet weight of 650 mg.

Excipients of the film coating: mixture for film coating “Opadry® 20A220058 yellow” [hypromellose 2910 – 33.75%, hypromellose – 33.75%, talc – 20%, titanium dioxide – 11.1%, iron oxide yellow dye – 1.4%] – up to a film-coated tablet weight of 665 mg.

10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (4) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
15 pcs. – contour cell blisters (2) – cardboard packs.
15 pcs. – contour cell blisters (3) – cardboard packs.
15 pcs. – contour cell blisters (4) – cardboard packs.
15 pcs. – contour cell blisters (6) – cardboard packs.

Film-coated tablets from yellow with a brownish tint to light brown in color, capsule-shaped, biconvex, with a score; the cross-section shows a core from grayish-yellow to brownish-gray in color; inclusions are allowed.

1 tab.
Hesperidin 100 mg
Diosmin 900 mg

Excipients: crospovidone (XL-10) – 91 mg, sodium stearyl fumarate – 26 mg, talc – 13 mg, microcrystalline cellulose 102 – up to a core tablet weight of 1300 mg.

Excipients of the film coating: mixture for film coating “Opadry® 20A220058 yellow” [hypromellose 2910 – 33.75%, hypromellose – 33.75%, talc – 20%, titanium dioxide – 11.1%, iron oxide yellow dye – 1.4%] – up to a film-coated tablet weight of 1330 mg.

10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (4) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
15 pcs. – contour cell blisters (2) – cardboard packs.
15 pcs. – contour cell blisters (3) – cardboard packs.
15 pcs. – contour cell blisters (4) – cardboard packs.
15 pcs. – contour cell blisters (6) – cardboard packs.

Table of Contents

→ TABLE OF CONTENTS